ViiV Healthcare B.V.

ViiV Healthcare B.V. is a United Kingdom-based specialist pharmaceutical company dedicated to HIV prevention, treatment and long-term care. The business was created in 2009 by GSK and Pfizer by combining their HIV operations, with the purpose of giving HIV research and commercial activities a dedicated organizational focus rather than managing them as one therapeutic area within broader pharmaceutical portfolios. Japan's Shionogi later became a shareholder and contributed HIV assets and research capabilities to the company. GSK remains the controlling shareholder and provides much of the corporate infrastructure behind ViiV. The company operates across the HIV medicines lifecycle, including discovery research, clinical development, regulatory submissions, manufacturing, access programs and commercial distribution. Its portfolio covers several treatment classes, including nucleoside and nucleotide reverse-transcriptase inhibitors, integrase inhibitors, entry and attachment inhibitors, and long-acting injectable therapies. Major products associated with ViiV include dolutegravir brands such as Tivicay, combination products such as Triumeq and Dovato, the two-drug regimen Juluca, the long-acting cabotegravir products Vocabria and Apretude, the fixed-dose injectable HIV treatment Cabenuva developed with Janssen, and earlier products including Ziagen and Epivir. Portfolio availability and marketing authorization vary by country. ViiV's principal strategic distinction is its single-disease focus. Rather than competing as a general pharmaceutical company, it positions itself as a dedicated HIV specialist with capabilities spanning prevention, first-line and treatment-experienced patient care, pediatric treatment, adherence support and public-health access. The company has emphasized simplified regimens, durable viral suppression, reduced pill burden and long-acting administration. Its cabotegravir-based products have extended the business beyond daily oral treatment into HIV prevention and injectable treatment, while its dolutegravir franchise has been central to global HIV treatment programs. The company also conducts research into new mechanisms and formulations, including long-acting medicines, and works with public-health organizations, governments, generic manufacturers and community groups to expand access. ViiV has used voluntary licensing and access-oriented commercial arrangements for selected medicines, particularly in lower-income countries, although the affordability and availability of HIV medicines remain subjects of continuing public debate. Its Positive Action program supports community and civil-society organizations working on HIV-related stigma, prevention, testing, treatment literacy and social inclusion. ViiV is not a separately listed public company and does not have its own stock-market ticker. It is a corporate subsidiary and joint-venture-style operating company within the GSK group. The legal name supplied for this record is ViiV Healthcare B.V.; public-facing materials generally use the shorter name ViiV Healthcare. The company remains active and is one of the most prominent specialist HIV pharmaceutical organizations in the global market.

ViiV Healthcare was established in 2009 when GSK and Pfizer combined their HIV research and commercial operations. The venture was designed as a focused HIV company at a time when the disease area was becoming increasingly specialized, with treatment requiring long-term combination therapy, resistance management, adherence support and close attention to public-health delivery. Its creation brought together GSK's established HIV portfolio and Pfizer's HIV assets, including the CCR5 antagonist maraviroc. From its beginning, ViiV was structured as a dedicated operating company rather than a conventional independent pharmaceutical corporation. GSK became the controlling shareholder, Pfizer retained a minority interest, and the company used the combined research, development, manufacturing and commercial resources of its parents. Shionogi later joined the ownership structure and contributed intellectual property and development collaboration related to dolutegravir, an integrase inhibitor that became one of the central medicines in modern HIV treatment. The early portfolio included established medicines such as Ziagen, Epivir, Combivir and Kivexa, as well as newer products and pipeline candidates. The principal strategic breakthrough was the development and commercialization of dolutegravir. Marketed as Tivicay and incorporated into fixed-dose combinations including Triumeq and Dovato, dolutegravir became important because of its strong antiviral activity, high barrier to resistance and suitability for simplified regimens. ViiV subsequently broadened the treatment portfolio with Juluca, a two-drug regimen pairing dolutegravir with rilpivirine, and with products intended for people with multidrug-resistant HIV, such as Rukobia. A second major phase began with the development of long-acting cabotegravir. ViiV's injectable technology was used in partnership with Janssen to create Cabenuva, a long-acting complete treatment regimen combining cabotegravir and rilpivirine. The company also developed cabotegravir as a prevention medicine. Its approval as Apretude provided an HIV pre-exposure prophylaxis option administered at intervals rather than taken as a daily oral tablet. These products changed ViiV's role from an established oral-treatment supplier into a significant participant in long-acting HIV treatment and prevention. Access has remained a prominent part of ViiV's identity. The company has used voluntary licensing, tiered pricing, supply agreements and partnerships with governments and international organizations for selected HIV medicines. It has also supported community organizations through Positive Action, a program addressing stigma, prevention, testing, treatment literacy and the social factors that affect HIV outcomes. Such activities reflect the unusual position of HIV pharmaceutical companies, whose commercial decisions are closely connected with global public-health policy. The company has faced the same debates that affect the wider HIV industry, including questions about patent duration, pricing, generic competition and the speed at which new medicines reach lower-income countries. ViiV's response has generally combined protection of intellectual property in commercial markets with licensing and access mechanisms for specified countries and patient populations. Availability, reimbursement and regulatory status remain different across jurisdictions. ViiV continues to operate as an active GSK-controlled specialist company. Its business is centered on HIV research, branded medicines, prevention and long-acting delivery, while its partnerships extend the reach of its products beyond the markets in which it directly commercializes them. The supplied legal-name form, ViiV Healthcare B.V., refers to a corporate entity within this wider operating structure; the public brand is normally written as ViiV Healthcare.

1. 2021Cabenuva and Apretude launch in the United States

   Long-acting cabotegravir becomes available in the United States both as part of injectable HIV treatment and as the prevention product Apretude.

   Source
2. 2019Dovato receives regulatory approval

   Dovato, a two-drug dolutegravir and lamivudine regimen, is approved in the United States for adults with HIV-1 without prior antiretroviral treatment.

   Source
3. 2017Deborah Waterhouse becomes chief executive

   Deborah Waterhouse succeeds as ViiV Healthcare's chief executive, leading the company through expansion of its treatment and long-acting pipeline.

   Source
4. 2014Triumeq is approved

   The FDA approves Triumeq, a once-daily fixed-dose combination containing dolutegravir, abacavir and lamivudine.

   Source
5. 2013Tivicay receives United States approval

   The FDA approves dolutegravir as Tivicay for use with other antiretroviral agents in the treatment of HIV-1 infection.

   Source
6. 2012Dolutegravir partnership advances

   ViiV and Shionogi advance development of dolutegravir, an integrase inhibitor that later becomes a core ViiV franchise.

   Source
7. 2009ViiV Healthcare is established

   GSK and Pfizer combine their HIV businesses to create a dedicated specialist company.

   Source

A global, specialist HIV company focused on innovative oral and long-acting medicines, HIV prevention, treatment simplification and access-oriented public-health partnerships.

• TivicayHIV integrase inhibitor2013

  Tivicay is the brand name for dolutegravir, an integrase strand transfer inhibitor used with other antiretroviral medicines to treat HIV-1 infection. It became a foundation of ViiV's modern portfolio because of its potency, once-daily use in many treatment settings and high barrier to resistance. Authorization details and approved patient populations differ by market.

• TriumeqFixed-dose HIV treatment combination2014

  Triumeq combines dolutegravir, abacavir and lamivudine in a single-tablet regimen. It was designed to reduce pill burden while retaining a three-drug treatment approach. The product is subject to patient-selection requirements, including consideration of abacavir-associated hypersensitivity risk and relevant genetic testing in markets where such testing is recommended.

• DovatoTwo-drug HIV treatment combination2019

  Dovato is a once-daily fixed-dose combination of dolutegravir and lamivudine. It represents ViiV's treatment-simplification strategy by providing a complete two-drug regimen for eligible adults. Its use depends on regulatory labeling, viral-resistance history and clinical circumstances.

• JulucaTwo-drug HIV treatment combination2017

  Juluca combines dolutegravir with rilpivirine as a complete two-drug regimen for adults whose HIV is already virologically suppressed and who meet the relevant treatment criteria. It is part of ViiV's effort to offer durable viral suppression with fewer active medicines in an appropriately selected population.

• CabenuvaLong-acting injectable HIV treatment2021

  Cabenuva is a long-acting injectable complete HIV treatment regimen based on cabotegravir from ViiV and rilpivirine from Janssen. It is administered by healthcare professionals at scheduled intervals after assessment of treatment suitability. The product was a major step away from daily oral therapy for appropriately selected adults.

• ApretudeHIV pre-exposure prophylaxis2021

  Apretude is an extended-interval injectable formulation of cabotegravir used for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV. It is intended for people at risk of HIV and requires an initiation and continuing injection schedule, together with HIV testing and clinical follow-up.

• VocabriaOral cabotegravir and long-acting treatment support2021

  Vocabria contains cabotegravir and is used in association with long-acting rilpivirine for the treatment of HIV in eligible adults. Depending on the jurisdiction and regimen, oral cabotegravir can support initiation or provide oral coverage around injections. It forms part of ViiV's long-acting treatment platform.

• RukobiaHIV attachment inhibitor2020

  Rukobia is the brand name for fostemsavir, an attachment inhibitor used with other antiretroviral medicines in heavily treatment-experienced adults with multidrug-resistant HIV-1 whose current regimen cannot otherwise provide a complete suppressive regimen. It addresses a specialized treatment population with limited remaining options.

• ZiagenNucleoside reverse-transcriptase inhibitor1999

  Ziagen contains abacavir, a nucleoside reverse-transcriptase inhibitor used in combination with other antiretroviral medicines. It is also a component of combination products such as Triumeq. Its use requires attention to the risk of abacavir hypersensitivity and applicable genetic screening recommendations.

• EpivirNucleoside reverse-transcriptase inhibitor1995

  Epivir is the brand name for lamivudine, an established nucleoside reverse-transcriptase inhibitor used in HIV combination therapy. Lamivudine is also included in several fixed-dose combinations and has been important in expanding simple, broadly deployable antiretroviral regimens.

• 1992Positive Action

  Global

  Positive Action is ViiV's long-running community and social-impact program supporting organizations addressing HIV prevention, stigma, testing, treatment access, adherence and the wider social conditions affecting people living with HIV.

  Outcome. The program has provided grants and partnerships to community and civil-society organizations in multiple regions. Specific annual results vary by program and are reported separately.

  Source

• 2018Move toward long-acting HIV treatment and preventionGeneration change

  Daily oral treatment remains effective but can be difficult for some patients because of adherence, stigma, privacy and treatment fatigue.

  What changed. ViiV invested in long-acting cabotegravir development for both treatment and pre-exposure prophylaxis, including collaboration with Janssen for Cabenuva.

  Aftermath. The resulting approvals created an injectable treatment and prevention franchise and broadened ViiV's role in HIV care beyond oral medicines.

  Source
• 2012Expansion of the dolutegravir platformStrategy

  The company sought to strengthen its HIV portfolio with an integrase inhibitor that could support both standalone and fixed-dose combination products.

  What changed. ViiV and Shionogi advanced dolutegravir development, leading to the Tivicay brand and later combination regimens.

  Aftermath. Dolutegravir became one of ViiV's most important treatment platforms and supported the company's expansion in first-line and simplified HIV therapy.

  Source
• 2009Creation of a dedicated HIV companyM&A

  GSK and Pfizer held substantial HIV portfolios but chose to combine their operations into a specialist company focused on one disease area.

  What changed. The companies formed ViiV Healthcare, with GSK as controlling shareholder and Pfizer retaining a minority interest.

  Aftermath. ViiV became a dedicated platform for HIV research, development, access programs and commercialization rather than a conventional broad-therapy pharmaceutical division.

  Source

• 2022ViiV expands licensing arrangements for generic dolutegravir

  ViiV continued access-oriented licensing and supply arrangements intended to support production and distribution of quality-assured dolutegravir-based medicines in lower-income countries.

  Other
  Source
• 2022ViiV Healthcare expands access licensing for long-acting cabotegravir for PrEP

  ViiV announced a voluntary licensing arrangement intended to enable generic production of long-acting cabotegravir for HIV prevention in selected low- and lower-middle-income countries after regulatory and manufacturing requirements are met.

  Other
  Source
• 2022ViiV Healthcare and Medicines Patent Pool announce cabotegravir licensing agreement

  The agreement was designed to support access to generic long-acting cabotegravir for HIV prevention in eligible countries through sublicensing to manufacturers.

  Other
  Source
• 2021ViiV Healthcare receives approval for Apretude as long-acting HIV pre-exposure prophylaxis

  The United States authorized injectable cabotegravir, marketed as Apretude, for HIV pre-exposure prophylaxis in people at risk of sexually acquiring HIV. The decision established a major prevention franchise for ViiV alongside its treatment portfolio.

  Product launchRegulation
  Source
• 2021Long-acting cabotegravir and rilpivirine approved for HIV treatment

  The United States approved Cabenuva, a long-acting injectable regimen involving cabotegravir from ViiV and rilpivirine from Janssen, for adults whose virus is already suppressed on a stable regimen.

  Product launchProduct generationRegulation
  Source
• 2021ViiV Healthcare launches Apretude for HIV pre-exposure prophylaxis in the United States

  The U.S. Food and Drug Administration approved long-acting injectable cabotegravir, marketed as Apretude, for HIV pre-exposure prophylaxis in people at risk of sexually acquiring HIV.

  Product launch
  Source
• 2021FDA approves Cabenuva as the first complete long-acting injectable HIV treatment regimen

  The FDA approved Cabenuva, a monthly injectable combination of cabotegravir and rilpivirine, for adults whose HIV is virologically suppressed on a stable antiretroviral regimen.

  Product launch
  Source
• 2020ViiV Healthcare receives U.S. approval for Rukobia

  The FDA approved fostemsavir, marketed as Rukobia, for adults with multidrug-resistant HIV-1 infection whose current antiretroviral regimen was failing because of resistance, intolerance, or safety concerns.

  Product launch
  Source

1. ViiV Healthcare: About us
2. ViiV Healthcare: Leadership
3. ViiV Healthcare: Our medicines
4. ViiV Healthcare: HIV community access
5. U.S. Food and Drug Administration: Apretude approval
6. U.S. Food and Drug Administration: Cabenuva approval
7. U.S. Food and Drug Administration: Tivicay approval
8. Dolutegravir partnership advances
9. Triumeq is approved
10. Dovato receives regulatory approval
11. Positive Action
12. Move toward long-acting HIV treatment and prevention
13. ViiV Healthcare expands access licensing for long-acting cabotegravir for PrEP
14. ViiV Healthcare and Medicines Patent Pool announce cabotegravir licensing agreement
15. ViiV Healthcare launches Apretude for HIV pre-exposure prophylaxis in the United States
16. FDA approves Cabenuva as the first complete long-acting injectable HIV treatment regimen
17. ViiV Healthcare receives U.S. approval for Rukobia